Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- China rules the $94-trillion global infrastructure market. India wants a share of the pie
- Incentives for R&D: New foreign trade policy to retain key schemes despite WTO trouble
- The Rise and fall of Prompt Engineering: A short-lived revolution
- Luxury car brands expand footprint as demand from Tier II-III cities rise